Sonoma Pharmaceuticals, Inc.

NasdaqCM:SNOA Rapport sur les actions

Capitalisation boursière : US$3.7m

Sonoma Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Sonoma Pharmaceuticals's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 11.5% per year.

Informations clés

-0.7%

Taux de croissance des bénéfices

34.1%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie6.0%
Taux de croissance des recettes-11.5%
Rendement des fonds propres-91.7%
Marge nette-35.9%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 17
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Aug 27
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Jul 12
The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

May 26
Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Aug 11

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sep 30
Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sonoma Pharmaceuticals reports FQ2 results

Nov 20

Ventilation des recettes et des dépenses

Comment Sonoma Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqCM:SNOA Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2413-572
31 Mar 2413-582
31 Dec 2312-572
30 Sep 2312-681
30 Jun 2313-690
31 Mar 2313-590
31 Dec 2213-7100
30 Sep 2213-6100
30 Jun 2213-5100
31 Mar 2213-5100
31 Dec 2112-690
30 Sep 2115-590
30 Jun 2117-590
31 Mar 2119-591
31 Dec 2021-3111
30 Sep 2020-4121
30 Jun 2019-5131
31 Mar 2018-4141
31 Dec 1918-5141
30 Sep 1919-6161
30 Jun 1919-8172
31 Mar 1919-12192
31 Dec 1818-13202
30 Sep 1818-14202
30 Jun 1817-14202
31 Mar 1817-14202
31 Dec 1717-12191
30 Sep 1716-9182
30 Jun 1714-9182
31 Mar 1713-9172
31 Dec 1611-9172
30 Sep 1610-14162
30 Jun 168-16162
31 Mar 169-15162
31 Dec 1511-13152
30 Sep 1512-14142
30 Jun 1514-10132
31 Mar 1514-8122
31 Dec 14131122
30 Sep 14136122
30 Jun 14145123
31 Mar 14144123
31 Dec 1314-6123

Des revenus de qualité: SNOA is currently unprofitable.

Augmentation de la marge bénéficiaire: SNOA is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: SNOA is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.

Accélération de la croissance: Unable to compare SNOA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: SNOA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement des fonds propres

ROE élevé: SNOA has a negative Return on Equity (-91.66%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé